MSH2 and ovarian adenocarcinoma: Ovarian adenocarcinoma cell line research has revealed that loss of hMLH1 or hMSH2 can lead to an approximately two-fold increase in cisplatin, and a 1.3-fold increase in carboplatin resistance (53, 54).